3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Renal Cell
77
Kidney Neoplasms
23
Prostatic Neoplasms
22
Neoplasm Metastasis
13
Colorectal Neoplasms
10
Neoplasms
8
Melanoma
7
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Stomach Neoplasms
5
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Urologic Neoplasms
2
Triple Negative Breast Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Hereditary leiomyomatosis and renal cell cancer
2
Hematologic Neoplasms
2
Financial Stress
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
13
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
dodecyl maltoside
5
Radiotherapy
5
Cystoscopy
5
apaziquone
4
ALT-803
4
tislelizumab
3
5-aminolevulinic acid hexyl ester
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
Administration, Intravesical
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
Bevacizumab
×
Genitourinary
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled